Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma

C. Baiocchi, G. Landonio, G. Balzarini, C. Cacioppo, M. Calgaro, M. Ferrari, O. Gottardi, M. Majno, F. Scanzi, E. Ghislandi, B. Brando

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods: Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results: Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a 'score' system, was also related to a better clinical response. Conclusions: Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

Original languageEnglish
Pages (from-to)348-352
Number of pages5
JournalTumori
Volume80
Issue number5
Publication statusPublished - 1994

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Interleukin-2
Eosinophils
Antibodies
Lymphocytes
Lymphocyte Subsets
Leukocyte Count
Interferons
Therapeutics
Neoplasm Metastasis

Keywords

  • alpha-2 interferon
  • biologic effects
  • interleukin-2
  • metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma. / Baiocchi, C.; Landonio, G.; Balzarini, G.; Cacioppo, C.; Calgaro, M.; Ferrari, M.; Gottardi, O.; Majno, M.; Scanzi, F.; Ghislandi, E.; Brando, B.

In: Tumori, Vol. 80, No. 5, 1994, p. 348-352.

Research output: Contribution to journalArticle

Baiocchi, C, Landonio, G, Balzarini, G, Cacioppo, C, Calgaro, M, Ferrari, M, Gottardi, O, Majno, M, Scanzi, F, Ghislandi, E & Brando, B 1994, 'Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma', Tumori, vol. 80, no. 5, pp. 348-352.
Baiocchi, C. ; Landonio, G. ; Balzarini, G. ; Cacioppo, C. ; Calgaro, M. ; Ferrari, M. ; Gottardi, O. ; Majno, M. ; Scanzi, F. ; Ghislandi, E. ; Brando, B. / Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma. In: Tumori. 1994 ; Vol. 80, No. 5. pp. 348-352.
@article{d596bd0ed0d941edb10c24778e448192,
title = "Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma",
abstract = "Background: Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods: Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results: Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33{\%}) and 3 stable disease (20{\%}): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a 'score' system, was also related to a better clinical response. Conclusions: Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.",
keywords = "alpha-2 interferon, biologic effects, interleukin-2, metastatic renal cell carcinoma",
author = "C. Baiocchi and G. Landonio and G. Balzarini and C. Cacioppo and M. Calgaro and M. Ferrari and O. Gottardi and M. Majno and F. Scanzi and E. Ghislandi and B. Brando",
year = "1994",
language = "English",
volume = "80",
pages = "348--352",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Possible correlation between some biologic effects and the clinical course in patients treated with continuous infusion of interleukin-2 plus alpha-2 interferon for metastatic renal cell carcinoma

AU - Baiocchi, C.

AU - Landonio, G.

AU - Balzarini, G.

AU - Cacioppo, C.

AU - Calgaro, M.

AU - Ferrari, M.

AU - Gottardi, O.

AU - Majno, M.

AU - Scanzi, F.

AU - Ghislandi, E.

AU - Brando, B.

PY - 1994

Y1 - 1994

N2 - Background: Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods: Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results: Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a 'score' system, was also related to a better clinical response. Conclusions: Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

AB - Background: Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods: Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results: Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a 'score' system, was also related to a better clinical response. Conclusions: Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

KW - alpha-2 interferon

KW - biologic effects

KW - interleukin-2

KW - metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028598145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028598145&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 348

EP - 352

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -